2 completed, 2 recruiting. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 2 |
Follow DNX-2401: new trials by email Literature Review of DNX-2401 trials Research Report on DNX-2401
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases DNX-2401 - Melanoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 50 | 2026-09-25 | 2026-11-02 |
| MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Oncolytic Adenovirus Ad5-DNX-2401, Therapeutic Conventional Surgery - IDH1 wt Allele, Recurrent Anaplastic Astrocytoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2019-02-12 | 2026-09-25 |
| Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas DNX-2401 - Brainstem Glioma, Neoadjuvant Therapy | Phase 1 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 12 | 2017-05-26 | 2023-04-06 |
| DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas DNX-2401, Tumor Removal - Brain Cancer, Central Nervous System Diseases | Phase 1 | Completed | DNAtrix, Inc. | 37 | 2009-02-01 | 2018-07-16 |
Glioma (2) · Astrocytoma (1) · Brain Neoplasms (1) · Central Nervous System Diseases (1) · Glioblastoma (1) · Gliosarcoma (1) · Melanoma (1)
M.D. Anderson Cancer Center (2) · Clinica Universidad de Navarra, Universidad de Navarra (1) · DNAtrix, Inc. (1)
United States (3) · Spain (1)
Christopher Alvarez-Breckenridge, MD, PHD (1) · Frederick F Lang (1) · Frederick F. Lang, MD, BS (1) · Jaime Gallego, MD, PhD (1)
PMID 17848677, PMID 18089777, PMID 24903904, PMID 29432077, PMID 31138805, PMID 34824133, PMID 35767439, PMID 38311852